Last reviewed · How we verify
Ilaris (CANAKINUMAB)
Ilaris (Canakinumab) is a biologic medication originally developed and currently owned by Novartis Pharmaceuticals. It targets interleukin-1 beta, a protein involved in inflammation, and is used to treat various inflammatory conditions, including gout, periodic fever syndromes, and juvenile arthritis. Ilaris is a monoclonal antibody, not a small molecule, and has been FDA-approved since 2009. It has a long half-life of 26 days, allowing for less frequent dosing. Ilaris is a patented medication with no generic manufacturers available.
At a glance
| Generic name | CANAKINUMAB |
|---|---|
| Sponsor | Novartis Pharms |
| Drug class | Non-Standardized Plant Allergenic Extract [EPC] |
| Target | Interleukin-1 beta |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2009 |
| Annual revenue | 1369 |
Approved indications
- Articular gout
- Cryopyrin associated periodic syndrome
- Deficiency of mevalonate kinase
- Familial Mediterranean fever
- Systemic onset juvenile chronic arthritis
- TNF receptor-associated periodic fever syndrome (TRAPS)
Common side effects
- Nasopharyngitis
- Diarrhea
- Influenza
- Rhinitis
- Nausea
- Headache
- Bronchitis
- Gastroenteritis
- Pharyngitis
- Weight increased
- Musculoskeletal pain
- Vertigo
Serious adverse events
- Infections
- Intra-abdominal abscess
- Vertigo
Key clinical trials
- Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD (PHASE3)
- Study of Canakinumab in Patients With Myelofibrosis (PHASE2)
- IL1 Inhibition in FOP
- Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (PHASE3)
- Evaluation of Canakinumab in High-Risk Former-Smokers (PHASE2)
- Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis (PHASE2)
- Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia (PHASE2)
- Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ilaris CI brief — competitive landscape report
- Ilaris updates RSS · CI watch RSS
- Novartis Pharms portfolio CI